Christopher Fanger

USPTO Granted Patents = 29 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 5.9

ph-index = 9

Forward Citations = 157(Granted Patents)

Company Filing History:

16 out of 49

Hydra Biosciences, Inc.

patents

6 out of 17

Cadent Therapeutics, Inc.

Eli Lilly and Company

6. 1 out of 832,680

Other

patents

Years Active: 2010-2025

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12414927 - CXCR5 antagonists and methods of treating diseases or disorders using same (2025-09-16),

2. 12358929 - NMDA receptor modulators and uses thereof (2025-07-15),

3. 12162890 - Heteroaromatic NMDA receptor modulators and uses thereof (2024-12-10),

4. 11807650 - NMDA receptor modulators and uses thereof (2023-11-07),

5. 11648253 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2023-05-16),

6. 11541057 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2023-01-03),

7. 11274107 - NMDA receptor modulators and uses thereof (2022-03-15),

8. 11236104 - Heteroaromatic NMDA receptor modulators and uses thereof (2022-02-01),

9. 10973825 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2021-04-13),

10. 10626122 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-04-21),

11. 10500205 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2019-12-10),

12. 10351567 - Methods and compositions for treating pain (2019-07-16),

13. 9895356 - Methods and compositions for treating anxiety (2018-02-20),

14. 9815838 - Methods and compositions for treating pain (2017-11-14),

15. 9486455 - Compounds for modulating TRPV3 function (2016-11-08),

Title: Christopher Fanger: Innovator in Neuropsychiatric Treatments

Introduction

Christopher Fanger, a prominent inventor located in Bolton, MA, has made significant contributions to the field of neuropsychiatric disorder treatments through his innovative research. With a remarkable portfolio of 27 patents, Fanger continues to shape the landscape of pharmaceutical developments, particularly in the modulation of the NMDA receptor.

Latest Patents

Fanger's latest patents include groundbreaking work on heteroaromatic NMDA receptor modulators and their applications in treating neuropsychiatric disorders. The compounds discussed in his patents hold promise for the treatment of conditions such as schizophrenia and major depressive disorder. These patents not only detail the pharmaceutical compositions but also provide methods for synthesizing these essential compounds aimed at modulating the NMDA receptor effectively.

Career Highlights

Throughout his career, Fanger has been associated with renowned companies in the biotech and pharmaceutical industry, including Hydra Biosciences, Inc., and Cadent Therapeutics, Inc. His roles in these organizations have allowed him to advance his research and contribute to the development of new therapeutic strategies for challenging psychiatric conditions.

Collaborations

Fanger has collaborated with brilliant minds in the field, including Magdalene M. Moran and Jayhong A. Chong, enhancing the impact of his research and inventions. These collaborations have fostered an environment of innovation and have led to the development of novel approaches to treating neuropsychiatric disorders.

Conclusion

Christopher Fanger’s contributions to the field of neuropsychiatry through his extensive patent portfolio highlight his commitment to advancing medical science. With ongoing research and innovative approaches, he continues to make strides that could significantly improve the quality of life for individuals suffering from neuropsychiatric disorders.

This text is generated by artificial intelligence and may not be accurate.